# Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.

Study · id `cardio:ct-nct05760456` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05760456](<https://clinicaltrials.gov/study/NCT05760456>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05760456

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 140 participants.

## Technical summary

Registry record NCT05760456. Randomized; no masking; primary purpose treatment. Start 2023-03-15 (anticipated); primary completion 2024-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT05760456, source copy `cardio:ctgov-nct05760456-2023-03-08`, retrieved 2026-10-26)
- Planned start: 2023-03-15 (anticipated) (ClinicalTrials.gov record NCT05760456, source copy `cardio:ctgov-nct05760456-2023-03-08`, retrieved 2026-10-26)
- Primary completion: 2024-05-31 (anticipated) (ClinicalTrials.gov record NCT05760456, source copy `cardio:ctgov-nct05760456-2023-03-08`, retrieved 2026-10-26)
- Completion: 2024-08-31 (anticipated) (ClinicalTrials.gov record NCT05760456, source copy `cardio:ctgov-nct05760456-2023-03-08`, retrieved 2026-10-26)
- Countries: Vietnam (ClinicalTrials.gov record NCT05760456, source copy `cardio:ctgov-nct05760456-2023-03-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05760456-2023-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.
- Condition: Type 2 Diabetes
- Intervention (Drug): DIDALA hard capsules
- Intervention (Drug): Metformin
- Lead sponsor: Centre of Clinical Pharmacology, Hanoi Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 39ce1e5a72559a6b498a5f449eb66fc89b35a53cd44bb2baa1e21e0da53274cb
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
